Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.
Dynamic BH3 profiling offers personalized lung cancer therapies
- Post author:admin
- Post published:April 9, 2025
- Post category:uncategorized
- Post comments:0 Comments